|
|
|
|
||
Re: Zenith trial Institutions already own 86%.(as of 9/30/17) per attached. http://www.nasdaq.com/symbol/bcrx/institutional-holdings The company has enough cash to get to 2019 and presumably positive ph3 results on 7353. They have another shelf offering for another $200M. Short selling has the price under $5. Under the last 2 offerings of both $8+ and $5+. Management has stated they are going it alone and raised the cash to do so. If that's the case, then shorts can churn the stock in the current channel until 2019. So I'm not sure what investors he was talking about, when he asked what are they waiting for, when comparing Bcrx valuation and Dyax valuation. Must have been talking about a hostile bidder, which no one on this board would be sorry to see. Only thing I can think of. I throw open the floor for their opinions on what investors he was talking about. I ask the Piper Jaffray analyst, Charles Duncan, to follow up on the comment at their conference end of November. |
return to message board, top of board |